The stock of Motif Bio PLC (LON:MTFB) is a huge mover today! The stock decreased 3.42% or GBX 1.25 on November 7, hitting GBX 35.25. About 354,308 shares traded hands or 175.66% up from the average. Motif Bio PLC (LON:MTFB) has declined 16.67% since April 7, 2016 and is downtrending. It has underperformed by 18.62% the S&P500.
The move comes after 8 months negative chart setup for the GBX 38.43M company. It was reported on Nov, 7 by Barchart.com. We have GBX 30.32 PT which if reached, will make LON:MTFB worth GBX 5.38M less.
Motif Bio PLC (LON:MTFB) Ratings Coverage
Out of 2 analysts covering Motif Bio Plc (LON:MTFB), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Motif Bio Plc has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. As per Tuesday, March 15, the company rating was maintained by Beaufort Securities. Northland Capital maintained the stock with “Buy” rating in Wednesday, March 23 report. The rating was maintained by Beaufort Securities with “Speculative Buy” on Wednesday, October 14. The firm has “Speculative Buy” rating given on Thursday, March 3 by Beaufort Securities. The stock of Motif Bio PLC (LON:MTFB) has “Speculative Buy” rating given on Thursday, July 23 by Beaufort Securities. The firm earned “Buy” rating on Thursday, August 27 by Northland Capital. The rating was maintained by Northland Capital with “Buy” on Wednesday, January 6. Northland Capital maintained Motif Bio PLC (LON:MTFB) rating on Tuesday, September 29. Northland Capital has “Buy” rating and GBX 114 price target. The firm has “Buy” rating by Northland Capital given on Friday, October 16. Northland Capital maintained Motif Bio PLC (LON:MTFB) rating on Wednesday, March 2. Northland Capital has “Buy” rating and GBX 114 price target.
Another recent and important Motif Bio PLC (LON:MTFB) news was published by Uk.Finance.Yahoo.com which published an article titled: “Motif Bio Plc (MTFB.L)” on April 02, 2015.
Motif Bio plc is a clinical-stage biopharmaceutical company. The company has a market cap of 38.43 million GBP. The Firm is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It currently has negative earnings. It operates in the development and commercialization of pharmaceutical formulations segment.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.